The award was for work leading to a patent submission on the metabolic modulation of the immune response through the anti-inflammatory action of itaconate.
LEAP funds provide winners with funds to help them achieve their milestones to further commercial licensing and/or investment potential.
Awards were selected by the Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship (SC), the Center for Drug Discovery (CDD), the Institute of Clinical and Translational Sciences (ICTS), and the Office of Technology Management (OTM), in conjunction with industry and venture capital domain experts.
Maxim Artyomov, PhD is an Assistant Professor in the Division of Immunobiology in the Department of Pathology & Immunology.